Catherine McCormick
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Catherine McCormick has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Wen Liu
AHN Cancer Institute, Allegheny Health Network, Pittsburgh, PA 15212, USA
2 shared publications- Yong Fan
Allegheny Health Network Cancer Institute, Pittsburgh, PA, USA; Department of Biomedical Engineering/Biological Sciences, Carnegie Mellon University, Pittsburgh, PA, USA
2 shared publications - Amir Alavi
Carnegie Mellon University
1 shared publication - Ann Zeleniak
Institute of Cellular Therapeutics, Allegheny Health Network, Pittsburgh, PA, 15212
1 shared publication Asako Tajima
Institute of Cellular Therapeutics, Allegheny Health Network, Pittsburgh, USA
1 shared publicationBenjamin Mizerak
Department of Chemical and Petroleum Engineering, University of Pittsburgh, Pittsburgh, USA
1 shared publication
Latest Publications
- 6 November 2024
- Published by Elsevier in Current Opinion in Genetics & Development
- Vol. 89, 102276
Engineering immune organoids to regenerate host immune system
- 6 November 2024
- Published by Elsevier in Current Opinion in Genetics & Development
- Vol. 89, 102276
Engineering immune organoids to regenerate host immune system
- 5 September 2022
- Published by Springer Nature in Nature Methods
- Vol. 19 (10) , 1306-1319
De novo construction of T cell compartment in humanized mice engrafted with iPSC-derived thymus organoids
Hematopoietic humanized (hu) mice are powerful tools for modeling the action of human immune system and are widely used for preclinical studies and drug discovery. However, generating a functional human T cell compartment in hu mice remains challenging, primarily due to the species-related differences between human and mouse thymus. While engrafting human fetal thymic tissues can support robust T cell development in hu mice, tissue scarcity and ethical concerns limit their wide use. Here, we describe the tissue engineering of human thymus organoids from inducible pluripotent stem cells (iPSC-thymus) that can support the de novo generation of a diverse population of functional human T cells. T cells of iPSC-thymus-engrafted hu mice could mediate both cellular and humoral immune responses, including mounting robust proinflammatory responses on T cell receptor engagement, inhibiting allogeneic tumor graft growth and facilitating efficient Ig class switching. Our findings indicate that hu mice engrafted with iPSC-thymus can serve as a new animal model to study human T cell-mediated immunity and accelerate the translation of findings from animal studies into the clinic.
- 5 September 2022
- Published by Springer Nature in Nature Methods
- Vol. 19 (10) , 1306-1319
De novo construction of T cell compartment in humanized mice engrafted with iPSC-derived thymus organoids
Hematopoietic humanized (hu) mice are powerful tools for modeling the action of human immune system and are widely used for preclinical studies and drug discovery. However, generating a functional human T cell compartment in hu mice remains challenging, primarily due to the species-related differences between human and mouse thymus. While engrafting human fetal thymic tissues can support robust T cell development in hu mice, tissue scarcity and ethical concerns limit their wide use. Here, we describe the tissue engineering of human thymus organoids from inducible pluripotent stem cells (iPSC-thymus) that can support the de novo generation of a diverse population of functional human T cells. T cells of iPSC-thymus-engrafted hu mice could mediate both cellular and humoral immune responses, including mounting robust proinflammatory responses on T cell receptor engagement, inhibiting allogeneic tumor graft growth and facilitating efficient Ig class switching. Our findings indicate that hu mice engrafted with iPSC-thymus can serve as a new animal model to study human T cell-mediated immunity and accelerate the translation of findings from animal studies into the clinic.